Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the proteas...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruijn, Winnie, Ibáñez, Cristina, Frisk, Pia, Bak Pedersen, Hanne, Alkan, Ali, Vella Bonanno, Patricia, Brkičić, Ljiljana S., Bucsics, Anna, Dedet, Guillaume, Eriksen, Jaran, Fadare, Joseph O., Fürst, Jurij, Gallego, Gisselle, Godói, Isabella P., Guerra Júnior, Augusto A., Gürsöz, Hakkı, Jan, Saira, Jones, Jan, Joppi, Roberta, Kerman, Saim, Laius, Ott, Madzikwa, Newman, Magnússon, Einar, Maticic, Mojca, Markovic-Pekovic, Vanda, Massele, Amos, Ogunleye, Olayinka, O'Leary, Aisling, Piessnegger, Jutta, Sermet, Catherine, Simoens, Steven, Tiroyakgosi, Celda, Truter, Ilse, Thyberg, Magnus, Tomekova, Kristina, Wladysiuk, Magdalena, Vandoros, Sotiris, Vural, Elif H., Zara, Corinne, Godman, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964878/
https://www.ncbi.nlm.nih.gov/pubmed/27516740
http://dx.doi.org/10.3389/fphar.2016.00197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964878/
https://www.ncbi.nlm.nih.gov/pubmed/27516740
http://dx.doi.org/10.3389/fphar.2016.00197

Ejemplares similares